After charming football aficionados with a glittering world cup, policy wonks with a BRICS meet, now Brazil is all set to woo the global pharma with a humdinger.
As the curtains are drawn on the spectacular foot ball world cup, Brazil is all set to unveil one of the foremost pharmaceutical events in the world, CPhI South America. This year’s event, following the recent football world cup provides an exciting time to invest and do business in Brazil, aver experts.
With patents coming to an end, the pharmaceutical industry is facing big challenges in the US and Europe. These issues have made emerging markets such as Latin America more attractive. Due to population growth, and an increment in their health coverage plus the growing economic situation of the region, the pharmaceutical market in Latin America is on a high growth trajectory.
In 2013, four Latin American countries, Brazil, Mexico, Venezuela, and Argentina, were in the top 25 for pharmaceutical sales and by 2022 their sales are expected to more than double. Brazil, the leading market in Latin America, is expected to become the fourth biggest market for pharmaceuticals by 2022 with its value estimated at US$ 61.05 billion (compared to US$ 26.56 billion in 2013.) Pharmaceutical sales within Latin America are expected to increase by 119 per cent from 2008 to 2021
According to a report by McCann Health, its pharmaceutical market is expected to grow as government expenditure on health is expected to increase from 46.4 per cent of total health expenditure in 2010 to 50.27 per cent by 2015. This increase provides an even brighter outlook for pharmaceutical companies in Brazil, as sales will increase with the increase in healthcare spending.
Also important to the Brazilian market are generic pharmaceutical sales. As spending increases, the generic market will play a greater role as the government looks for cost-effective ways to allow for the larger distribution of different medicines through its healthcare system. The pharmaceutical market for manufacturers also looks bright, as the Ministry of Health had announced in 2011 that it would invest US$ 881 million by the end of 2014 in the research and development sector.
South America is undergoing major changes in macro-economic environment, with a burgeoning middle-class and heightened job opportunities, which in turn has lead to an increased demand for healthcare and the pharmaceutical industry in general. This booming economy proves that there has never been a better time to invest in the South American pharma market and CPhI provides the ideal platform for companies to meet domestic buyers and suppliers, whilst also creating a networking opportunity to foster international partnerships.
CPhI South America, the numero uno pharma sourcing event co-located with ICSE, BioPh and Fi (Food Ingredients South America) will be held from August 5 to 7, 2014 at Expo Center Norte, Sao Paulo. This event brings together two of the most important and dynamic industries, the pharmaceutical and food industry, by co-locating with FiSA. The events will be mutually beneficial for attendees by exposing them to products and services that complement the collaborative industries.
CPhI South America is the top business event for accessing this growing market where pharmaceutical professionals from around the world come to network with domestic companies, build partnerships, learn about the market and discover new business opportunities.
According to the organisers, CPhI South America is the foremost business platform to access this growing market both in Brazil and the whole continent. With a rapid economic growth, huge population of 200 million, increase in healthcare spendings and a booming generic drug sector, this is a pharma market that cannot be neglected. The Brazilian pharma market has in the last decade changed radically. The government is strongly supporting the pharmaceutical industry especially the generic and biopharmaceutical sector with the aim to become global leaders.
The event will be beneficial for companies in many ways. While it will help to strengthen brands,it will enable exhibitors and visitors to meet face-to-face with a high quality audience. Outside companies and businessmen can establish new relationships in the South American market. This also provides an excellent opportunity to launch new products and services to international audience.
Given the expected growth in both the generic sector and the Brazilian market, many of the 2014 programmes provide attendees with relevant information to strengthen their position in or enter these emerging markets.
According to Chris Kilbee, Group Director Pharma at CPhI, this year, CPhI South America and co-located events will host more than 13,000 guests from over 38 different countries, representing leading suppliers and manufacturers from both the food and pharmaceutical industry. The varied attractions present at the event include on-site laboratories and ‘Business with Brazil’, new to this year. This year, the CPhI + Fi international conference programs which will run alongside exhibitions, will give valuable insight to the generics and super generics and natural extract markets. In addition, there will be presentations by ABRIFAR to address ‘How to do Business in Brazil.’
"The event will provide opportunities to meet with industry professionals and aid business development in one of pharma’s emerging markets. This year we expect a host of visitors from around the globe- with over 13,000 attendees from just under 40 countries", he adds.
The profile for exhibit includes suppliers of turnkey pharma plants, machinery & equipment for treatment of pharma raw materials, analytical instruments & lab reagents, testing instruments, microscopes, weighing machines, active pharma ingredients, tableting & capsulation units, packaging materials, glassware and pharma publications.
CPhI will feature zones for API’s, generic API’s, custom manufacturing, fine chemicals, intermediates, finished dosage, excipients/formulation and ingredients. Zoning segments will ensure easier navigation for visitors through the event for efficient time management. Faster movement between areas will give more time to network and do business. Targeted marketing will makes it easier for quality leads to stand amongst the crowd.
Among the exhibitors are some of India’s largest and most innovative companies. Overall trade, including pharmaceutical trade, has increased drastically over the past decade. Indian pharmaceutical companies consider Latin America as a destination for their international investment.
One of India’s largest pharmaceutical companies, Dr. Reddy’s, has manufacturing plants in Venezuela and is a major player in the Latin American pharmaceutical market. As this market continues to grow, Indian pharmaceutical companies will continue to see this region as a place for investment . Of particular interest is the growing generics market, which represents a large growth area for Indian exhibitors and companies.
Last year, CPhI South America was the sixth successful addition of the event, with over 13,000 attendees, many new interactions and collaborations were made and partnerships formed.
It proved to be the foremost event for collaborating two integral industries and providing opportunity to form symbiotic partnerships with industry leaders to shape the collective markets.
Last year, CPhI South America joined forces with Food Ingredients South America (FiSA) & Health Ingredients South America (HiSA), the region’s other primary super-conferences, to help stimulate further economic development within South America. The collaborative events attracted many international exhibitors representing the whole supply chain from countries including United States, Germany, Canada, Japan, China and India who were all keen to break into the South American market, and were pivotal in driving economical growth and innovation throughout the region. Signifying the importance of the co-located shows, attendance figures reached around 10,000 strong which was the most successful turnout to date.
Throughout the three show days an attractive series of lectures were presented, covering the current pharmaceutical industry trends and perspectives and keeping attendees up- to- date on subjects ranging from Drug Master Files (DMFs) to open innovation and legal procedures. Workshops, international business round tables and seminars were also offered, which proved particularly valuable to international exhibitors and featured hot topics such as “How to understand regulatory issues in Brazil”.
An overview of the regulatory affairs in Brazil was provided showcasing the favourable regulatory environment which no doubt makes it an ideal place for international companies to build partnerships and establish themselves.
A particular highlight of the last year show was the model laboratory, which all attendees were able to experience and learn more about equipment on offer. The lab presented modern equipment for analysis and production of tablets, preformulation testing and development of solid pharmaceutical forms.
“Latin America is one of the fastest growing regions for the pharmaceutical industry and is increasingly becoming a go-to destination for international companies looking to establish themselves in and form domestic partnerships with, particularly as the regulatory environment in so favourable. CPhI and its co-located events showed just how significant the synergy between pharma and food is and highlighted the growth opportunities that these two industries can provide when collaborating. The partnership is becoming more necessary as we see nutraceuticals and supplements play a pivotal role within the healthcare sector", said Erik Heemskerk, Brand Director, Emerging Markets at UBM Live.